Compare Charles Schwab Corporation Common Stock (SCHW) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles Schwab Corporation Common Stock vs Vertex Pharmaceuticals Incorporated — how do they compare? Charles Schwab Corporation Common Stock trades at $106.54 (market cap $184.81B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Charles Schwab Corporation Common Stock is the larger of the two by market cap, and Charles Schwab Corporation Common Stock pays a 1.2% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| SCHW | VRTX | |
|---|---|---|
Market Cap | $184.81B | $134.06B |
Sector | Financials | Health |
52-Week High | $113.65 | $557.96 |
52-Week Low | $85.35 | $376.62 |
Dividend Yield | 1.2% | — |
Enterprise Value | — | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles Schwab (SCHW) trades at $106.87, down 2.21% today, as technical indicators signal bearish momentum with price near key support at $106. Fundamentally, the company shows strength with Q2 2026 EPS beating estimates at $1.62 versus $1.56 expected, and revenue growth accelerating to $23.92B in 2025. Analyst sentiment remains positive with 57% buy ratings and a $122.14 consensus target, representing 14% upside potential from current levels.
The outlook remains favorable given strong earnings momentum and expanding digital asset offerings, though near-term technical weakness and competitive pressures from Vanguard's Altruist acquisition present risks. With robust cash flow generation and improving debt metrics, SCHW offers value for long-term investors despite current bearish technical signals.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
